Logo image of XNCR

XENCOR INC (XNCR) Stock Fundamental Analysis

NASDAQ:XNCR - Nasdaq - US98401F1057 - Common Stock - Currency: USD

9.65  +0.53 (+5.81%)

After market: 9.7 +0.05 (+0.52%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to XNCR. XNCR was compared to 558 industry peers in the Biotechnology industry. While XNCR seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, XNCR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XNCR had negative earnings in the past year.
XNCR had a negative operating cash flow in the past year.
In the past 5 years XNCR reported 4 times negative net income.
In the past 5 years XNCR reported 4 times negative operating cash flow.
XNCR Yearly Net Income VS EBIT VS OCF VS FCFXNCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

XNCR has a Return On Assets of -23.54%. This is in the better half of the industry: XNCR outperforms 75.81% of its industry peers.
XNCR has a Return On Equity of -33.29%. This is in the better half of the industry: XNCR outperforms 75.27% of its industry peers.
Industry RankSector Rank
ROA -23.54%
ROE -33.29%
ROIC N/A
ROA(3y)-14.92%
ROA(5y)-8.95%
ROE(3y)-20.68%
ROE(5y)-12.58%
ROIC(3y)N/A
ROIC(5y)N/A
XNCR Yearly ROA, ROE, ROICXNCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

XNCR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XNCR Yearly Profit, Operating, Gross MarginsXNCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

4

2. Health

2.1 Basic Checks

XNCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XNCR has more shares outstanding
XNCR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, XNCR has an improved debt to assets ratio.
XNCR Yearly Shares OutstandingXNCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
XNCR Yearly Total Debt VS Total AssetsXNCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

XNCR has an Altman-Z score of 0.43. This is a bad value and indicates that XNCR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of XNCR (0.43) is better than 65.59% of its industry peers.
XNCR has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.16, XNCR is not doing good in the industry: 68.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 0.43
ROIC/WACCN/A
WACC9.52%
XNCR Yearly LT Debt VS Equity VS FCFXNCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 5.89 indicates that XNCR has no problem at all paying its short term obligations.
XNCR has a Current ratio of 5.89. This is in the better half of the industry: XNCR outperforms 60.39% of its industry peers.
A Quick Ratio of 5.89 indicates that XNCR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.89, XNCR is in the better half of the industry, outperforming 60.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.89
Quick Ratio 5.89
XNCR Yearly Current Assets VS Current LiabilitesXNCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

XNCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.73%.
XNCR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.59%.
The Revenue has been decreasing by -6.75% on average over the past years.
EPS 1Y (TTM)-39.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.54%
Revenue 1Y (TTM)-19.59%
Revenue growth 3Y-26.22%
Revenue growth 5Y-6.75%
Sales Q2Q%155.62%

3.2 Future

The Earnings Per Share is expected to grow by 15.85% on average over the next years. This is quite good.
Based on estimates for the next years, XNCR will show a very strong growth in Revenue. The Revenue will grow by 47.56% on average per year.
EPS Next Y13.87%
EPS Next 2Y11.46%
EPS Next 3Y10.41%
EPS Next 5Y15.85%
Revenue Next Year78.94%
Revenue Next 2Y50.97%
Revenue Next 3Y41.15%
Revenue Next 5Y47.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XNCR Yearly Revenue VS EstimatesXNCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
XNCR Yearly EPS VS EstimatesXNCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XNCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XNCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XNCR Price Earnings VS Forward Price EarningsXNCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XNCR Per share dataXNCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.46%
EPS Next 3Y10.41%

More info and screens

0

5. Dividend

5.1 Amount

XNCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XENCOR INC

NASDAQ:XNCR (6/6/2025, 8:00:02 PM)

After market: 9.7 +0.05 (+0.52%)

9.65

+0.53 (+5.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners108.35%
Inst Owner Change6.07%
Ins Owners0.81%
Ins Owner Change1.47%
Market Cap686.79M
Analysts84.44
Price Target31.73 (228.81%)
Short Float %12.53%
Short Ratio8.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.47%
Min EPS beat(2)-7.54%
Max EPS beat(2)22.47%
EPS beat(4)2
Avg EPS beat(4)6.09%
Min EPS beat(4)-19.61%
Max EPS beat(4)29.05%
EPS beat(8)4
Avg EPS beat(8)-19.51%
EPS beat(12)6
Avg EPS beat(12)-11.45%
EPS beat(16)9
Avg EPS beat(16)98.06%
Revenue beat(2)2
Avg Revenue beat(2)110.82%
Min Revenue beat(2)55.9%
Max Revenue beat(2)165.74%
Revenue beat(4)3
Avg Revenue beat(4)51.42%
Min Revenue beat(4)-20.99%
Max Revenue beat(4)165.74%
Revenue beat(8)5
Avg Revenue beat(8)36.01%
Revenue beat(12)7
Avg Revenue beat(12)21.59%
Revenue beat(16)11
Avg Revenue beat(16)52.21%
PT rev (1m)2.85%
PT rev (3m)-5.46%
EPS NQ rev (1m)-9.83%
EPS NQ rev (3m)14.72%
EPS NY rev (1m)-13.73%
EPS NY rev (3m)12.77%
Revenue NQ rev (1m)12.38%
Revenue NQ rev (3m)25.56%
Revenue NY rev (1m)4.76%
Revenue NY rev (3m)-1.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.27
P/FCF N/A
P/OCF N/A
P/B 1.07
P/tB 1.1
EV/EBITDA N/A
EPS(TTM)-3.06
EYN/A
EPS(NY)-2.66
Fwd EYN/A
FCF(TTM)-2.43
FCFYN/A
OCF(TTM)-2.29
OCFYN/A
SpS1.83
BVpS8.99
TBVpS8.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.54%
ROE -33.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.92%
ROA(5y)-8.95%
ROE(3y)-20.68%
ROE(5y)-12.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.11%
Cap/Sales 7.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.89
Quick Ratio 5.89
Altman-Z 0.43
F-Score1
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)252.19%
Cap/Depr(5y)241.55%
Cap/Sales(3y)15.72%
Cap/Sales(5y)12.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.54%
EPS Next Y13.87%
EPS Next 2Y11.46%
EPS Next 3Y10.41%
EPS Next 5Y15.85%
Revenue 1Y (TTM)-19.59%
Revenue growth 3Y-26.22%
Revenue growth 5Y-6.75%
Sales Q2Q%155.62%
Revenue Next Year78.94%
Revenue Next 2Y50.97%
Revenue Next 3Y41.15%
Revenue Next 5Y47.56%
EBIT growth 1Y-19.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.92%
EBIT Next 3Y1.65%
EBIT Next 5Y5.51%
FCF growth 1Y-172.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1271.01%
OCF growth 3YN/A
OCF growth 5YN/A